TGFB1 and pulmonary fibrosis: In the physiological and pathological changes of pulmonary fibrosis, liproxstatin-1 can activate the Nrf2 pathway to downregulate transforming growth factor β1 (TGF-β1) and delay the progression of pulmonary fibrosis (118).